BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

AeroGen, Inc. (AEGN) Receives Fast Track Designation For Aerosolized Amikacin


10/19/2005 5:12:47 PM

MOUNTAIN VIEW, Calif., Feb. 22 /PRNewswire-FirstCall/ -- Aerogen, Inc. today announced that it has received Fast Track Designation from the U.S. FDA for the Combination Product: Amikacin Pulmonary Delivery System for Ventilator-Associated Pneumonia (VAP). The product is Aerogen's lead drug/device combination product incorporating Aerogen's OnQ(R) Aerosol Generator technology adapted for high efficiency aerosol delivery to patients on mechanical ventilators.

The Fast Track Designation program was created to facilitate the development and expedite the review of a new product that is intended for the treatment of serious or life-threatening conditions, and demonstrates the potential to address unmet medical needs for such conditions. The FDA stated that it granted Combination Product: Amikacin Pulmonary Delivery System Fast Track designation for the following reasons:

1. VAP is a significant cause of morbidity and mortality in the intensive care unit (ICU), with an associated mortality rate of up to 50%. Patients with VAP have significantly longer duration of mechanical ventilation, ICU stay and hospital stay. 2. While Gram-negative organisms associated with VAP can be treated with aminoglycosides intravenously, parenteral delivery results in poor penetration of drug into the respiratory secretions and can cause significant adverse systemic effects. Targeted delivery of amikacin directly to the lungs takes advantage of the concentration-dependent killing of aminoglycoside antibiotics and has the potential to hasten resolution of the infection. The combination of high antibiotic concentrations at the infection site with low serum levels offers the possibility of reducing systemic toxicity.

"We are excited about the potential to significantly improve the treatment of patients with VAP using Aerogen's aerosolized amikacin product and are delighted with FDA's decision to grant Fast Track Designation for our program," said Dr. Robert Fishman, Vice President of Scientific Affairs.

Aerogen, a specialty pharmaceutical company, develops products based on its OnQ Aerosol Generator technology to improve the treatment of respiratory disorders in the acute care setting. Aerogen has presented the results of its first Phase 2 clinical study evaluating delivery of aerosolized amikacin for the treatment of ventilator-associated pneumonia; an additional Phase 2 study is currently underway. Following amikacin, additional drug products targeting improved respiratory therapy in the acute care setting are in the feasibility and pre-clinical stages of development. Aerogen's Aeroneb(R) Professional Nebulizer System is marketed world-wide for use in hospitals. Aerogen's Aeroneb(R) Go Nebulizer for home use is currently marketed in the U.S., Japan and certain European countries. Aerogen also has development collaborations with pharmaceutical and biotechnology companies for use of its technology in the delivery of novel compounds that treat respiratory and other disorders. Aerogen is headquartered in Mountain View, California, with a campus in Galway, Ireland. For more information, visit http://www.aerogen.com/.

To the extent any statements made in this release relate to information that is not historical, these statements are necessarily forward-looking. As such, they are subject to the occurrence of many events outside of Aerogen's control and other uncertainties, and are subject to various risk factors that could cause Aerogen's actual results to differ materially from those expressed in any forward-looking statement. The risk factors include, without limitation, the need for additional funding, the inherent risks of product development, clinical outcomes, regulatory risks and risks related to proprietary rights, market acceptance and competition, and are described in Aerogen's reports and other filings with the U.S. Securities and Exchange Commission, including Aerogen's Annual Report on Form 10-K for the year ended December 31, 2003, filed with the Securities and Exchange Commission ("SEC") on April 14, 2004 and Aerogen's Quarterly Report filed on Form 10-Q for the quarter ended September 30, 2004 filed with the SEC on November 15, 2004. Aerogen does not undertake any obligation to update forward-looking statements.

Aerogen, Inc.

CONTACT: Jane E. Shaw, Ph.D. of Aerogen, Inc., +1-650-864-7333



Read at BioSpace.com

   
Pneumonia

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->